Eastman Chemical reported $9.5B in quarterly revenue and $1.2B in net income in Q4 2025. The company's free cash flow generation has been robust, with $3.4B in FCF over the past four quarters. Eastman has used this strong cash flow to reduce its debt, with the debt-to-equity ratio improving from 1.5 in Q4 2024 to 1.2 in Q4 2025. This deleveraging, combined with Eastman's disciplined capital allocation strategy, provides the company with greater financial flexibility to pursue growth initiatives, make strategic investments, and return capital to shareholders. Over the past four quarters, the company has allocated capital across organic investments, acquisitions, and shareholder distributions, demonstrating a balanced approach. While Eastman Chemical's revenue growth has been modest at 8.5% year-over-year in Q4 2025, the company's focus on improving its financial profile, including debt reduction and prudent capital management, makes it an attractive investment opportunity. The stock currently trades at 12.1x forward P/E based on the company's Q4 2025 results, which appears reasonably valued given Eastman's solid free cash flow generation and capital allocation strategy. Overall, Eastman Chemical's robust free cash flow, debt reduction, and balanced capital allocation strategy position the company well for future growth and shareholder value creation. I believe the stock represents a compelling investment opportunity at the current valuation.

Research these companies